TransMedics Group, Inc. Common Stock
TMDX
$74.75
+4.40%
TransMedics Group is a commercial-stage medical technology company that has built a proprietary Organ Care System (OCS) — a portable perfusion, optimization, and monitoring platform that keeps donor organs in near-physiologic condition outside the body — and pairs it with a growing national organ-logistics and aviation network to deliver hearts, lungs, and livers for transplant, displacing the decades-old cold-storage standard of care. Its competitive identity is that of a vertically integrated category creator rather than a simple device vendor: it sells the hardware, the single-use perfusion sets, and increasingly the transport service itself, giving it a defensible moat built on clinical data, transplant-center relationships, and logistics infrastructure that rivals cannot easily replicate. The current investor debate has shifted from pure growth enthusiasm to a tug-of-war over margin durability and execution, with recent headlines highlighting an earnings miss and margin compression that sent shares sharply lower, offset by bulls who point to strong top-line growth, a post-earnings bounce, and optionality from kidney and European expansion as reasons the sell-off is a long-term buying opportunity. Sentiment is therefore polarized between those who see a high-multiple growth story decelerating into a more capital-intensive phase and those who view the OCS network as a durable, multi-decade platform still in the early innings of penetrating a large transplant market.…
TMDX
TransMedics Group, Inc. Common Stock
$74.75
Related headlines
Investment Opinion: Should I buy TMDX Today?
Rating: Hold. The core thesis is that TMDX is a high-growth medtech leader with a defensible platform, but near-term margin compression and a severe downtrend warrant caution until there is evidence of stabilization. The analyst consensus is 'buy' with a mean rating of 1.85 and an average target of $98.73, implying +39.5% upside, but the wide target range ($65-$125) and neutral ratings from several major firms suggest the conviction is not uniform.
Supporting evidence includes revenue growth of 32.18% YoY in Q4 2025, a gross margin of 59.92% (still healthy in absolute terms), positive TTM free cash flow of $133.59M, and a cash-rich balance sheet with $488.87M. The PS ratio of 6.83x is elevated versus mature device peers (3-5x) but well below the stock's historical average (62.97x in Q4 2022), and the PEG of 0.051 suggests the market is pricing minimal growth. However, the EV/EBITDA of 27.72x is rich, and the forward PE of 31.4x is above the trailing PE of 21.7x due to the tax-benefit distortion.
Key risks that could invalidate the thesis include continued gross margin erosion below 55%, a revenue growth deceleration below 20%, or a failure to gain traction in kidney/European markets. The rating would upgrade to Buy if gross margins stabilize above 58% and revenue growth re-accelerates above 35%, or if the stock breaks above the $85-$90 resistance zone with volume. It would downgrade to Sell if gross margins fall below 55% or if revenue growth drops below 20%. Relative to its history and peers, TMDX appears undervalued on a growth-adjusted basis (PEG 0.051) but fairly valued to slightly expensive on EV/EBITDA; the stock is a show-me story.
Sign up to view all
TMDX 12-Month Price Forecast
TMDX presents a classic growth-versus-profitability debate: revenue growth remains robust at 32%, but margin compression and a severe stock downtrend have created a deeply discounted valuation (PS 6.83x vs. historical 62.97x). The analyst consensus is bullish with a $98.73 target, but the wide range ($65-$125) and neutral ratings from major firms reflect genuine uncertainty. We are neutral with medium confidence because the near-term technicals are bearish (stock near 52-week low, high beta) and margin trends are negative, but the long-term platform story and cash-rich balance sheet provide a margin of safety. An upgrade to bullish would require two consecutive quarters of gross margin stabilization above 58% and revenue growth above 30%; a downgrade to bearish would follow a break below the 52-week low of $60.105 or gross margin falling below 55%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransMedics Group, Inc. Common Stock's 12-month outlook, with a consensus price target around $98.73 and implied upside of +32.1% versus the current price.
Average Target
$98.73
0 analysts
Implied Upside
+32.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$65 - $125
Analyst target range
Coverage is solid for a mid-cap, with 11 analysts publishing targets and a consensus recommendation of "buy" (mean rating of 1.85 on a 1-5 scale where lower is more bullish). The average target price is $98.73, which against the current $70.78 implies roughly +39.5% upside — a meaningfully bullish consensus that stands in sharp contrast to the stock's -38.81% one-year performance. The distribution skews positive: recent institutional ratings show Piper Sandler at Overweight, Oppenheimer and Evercore at Outperform, Needham and Canaccord at Buy, against Stifel at Hold, JP Morgan at Neutral, and Morgan Stanley at Equal Weight — so the sell-side is net bullish but with a meaningful neutral contingent that has not capitulated despite the drawdown. The consensus is best characterized as cautiously bullish, with the buy-rated analysts betting that the growth story reasserts itself.
The target range of $65.00 to $125.00 is wide — a spread of $60, or roughly 61% of the average target — which signals genuine disagreement about the company's trajectory rather than strong conviction. The high target of $125.00 (about +76.6% from current levels) likely assumes multiple expansion back toward historical norms, re-acceleration from kidney and European expansion, and stabilization of gross margins; the low target of $65.00 (about -8.2% below current) prices in continued margin compression, competitive pressure, and a growth-to-value de-rating. Notably, the low target sits just above the 52-week low of $60.105, suggesting even the bears see limited further downside from here. The consensus EPS estimate of $5.40 and revenue estimate of $1.18 billion imply the Street expects roughly $1.18 billion in forward revenue — a substantial step up that, if delivered, would validate the growth thesis and support the current EV/Sales multiple; the wide dispersion and the fact that no major firm has upgraded since the February 2026 ratings cluster means the next catalyst (likely a quarterly print or a kidney/European milestone) will be decisive in resolving the bull-bear debate.
Bulls vs Bears: TMDX Investment Factors
The bear case currently has stronger near-term evidence: margin compression is accelerating (gross margin down ~340bps in 2025, operating margin halved from Q2 to Q4), the stock is in a relentless downtrend (-38.8% 1Y, near 52-week low), and earnings quality is distorted by a one-time tax benefit. However, the bull case is not without merit: revenue growth of 32% remains robust, the balance sheet is fortress-like with $489M cash, and the valuation has compressed to multi-year lows (PS 6.83x vs. 62.97x in 2022). The single most important tension is whether the margin deterioration is a temporary scaling cost or a structural shift toward a lower-margin, capital-intensive logistics model—if margins stabilize, the stock is deeply undervalued; if they continue to slide, the premium multiple could compress further.
Bullish
- Revenue growth remains robust at 32%: Q4 2025 revenue of $160.76M grew 32.18% YoY from $121.62M, and every 2025 quarter exceeded its 2024 counterpart, confirming a durable growth engine. This top-line momentum is well above the mid-single-digit to low-double-digit growth of large-cap medtech peers.
- Analyst consensus sees 39.5% upside: With 11 analysts covering, the mean rating is 1.85 (buy) and the average target is $98.73, implying +39.5% upside from $70.78. The low target of $65 is only 8.2% below current, suggesting limited further downside per the Street.
- Balance sheet provides ample runway: Cash of $488.87M and a current ratio of 7.14 give TMDX significant liquidity to fund its logistics build-out and kidney/European expansion without near-term financing risk. Debt-to-equity of 0.99 is manageable given the cash pile.
- Valuation has compressed to multi-year lows: The PS ratio has fallen from 62.97x in Q4 2022 to 6.83x today, an ~89% compression, while revenue has grown. The PEG of 0.051 is extraordinarily low, suggesting the market is pricing minimal growth value.
Bearish
- Margin compression is accelerating: Gross margin fell from 61.47% in Q1 2025 to 58.11% in Q4, and EBITDA margin dropped from 29.48% in Q2 to 20.19% in Q4. Operating margin nearly halved from 23.24% in Q2 to 13.23% in Q4, showing costs are outrunning revenue leverage.
- Stock in severe downtrend near 52-week low: TMDX is down 38.81% over one year and 42.31% YTD, trading at just 11.1% of its 52-week range ($60.105-$156.00). The recent -7.50% single-day plunge on above-average volume signals continued selling pressure.
- Earnings quality distorted by tax benefit: Q4 net income of $105.38M was inflated by an $83.75M income tax benefit, making the trailing PE of 21.7x misleading. The forward PE of 31.4x is higher than trailing, indicating normalized earnings are expected to be lower.
- High beta amplifies downside risk: Beta of 1.926 means TMDX is nearly twice as volatile as the market, with a max drawdown of -58.76% from peak. In a risk-off environment, this stock could see amplified losses, as evidenced by the -54.34% relative strength vs. SPY over one year.
TMDX Technical Analysis
TMDX is in a pronounced, sustained downtrend, with the stock down 38.81% over the trailing year and 42.31% year-to-date, a stark reversal from what was evidently a much higher prior valuation. At a current price of $70.78, the stock sits at roughly 11.1% of its 52-week range of $60.105 to $156.00 — meaning it is trading near the very bottom of its annual band, only about $10.68 above the 52-week low and more than $85 below the high. That positioning is characteristic of a falling-knife setup rather than a value opportunity: the stock has lost more than half its value from peak (max drawdown of -58.76%), and there is no evidence yet of a durable base forming. The one-year relative strength versus SPY of -54.34% underscores how severely this name has lagged a market that itself rose 15.53% over the same period.
Short-term momentum is deteriorating rather than stabilizing, which is the critical technical tell. The stock is down 19.16% over the past month versus a +1.22% gain for SPY (relative strength of -20.38%), and the most recent session alone saw a -7.50% plunge from $76.52 to $70.78 on volume of roughly 1.07 million shares. The three-month change of -4.33% is less bad than the one-month figure, which means the decline has actually accelerated into October rather than decelerating — a bearish divergence from the already-negative longer-term trend. The six-month change of -38.91% confirms that the damage is not a brief air pocket but a persistent, multi-quarter de-rating, and the fact that the stock rallied from roughly $64 in mid-May to nearly $95 in late August before rolling over again suggests rallies are being sold into rather than accumulated.
Key technical levels are now clearly defined and bearish in implication. Support sits at the 52-week low of $60.105 — a break below that level would confirm a fresh leg lower and likely trigger momentum-driven selling, while a hold there could mark the first credible floor. Resistance is layered: the $85-$90 zone where the August rally stalled, and ultimately the $156.00 52-week high, which is now a distant recovery target rather than a near-term reference. With a beta of 1.926, TMDX is nearly twice as volatile as the broad market, meaning position sizing must be materially smaller than a market-beta name and stop-loss discipline is essential; a 1.93 beta implies roughly 93% more price swing than SPY for a given market move, which amplifies both the downside risk of the current downtrend and the upside if a reversal ever takes hold.
Beta
1.93
1.93x market volatility
Max Drawdown
-58.8%
Largest decline past year
52-Week Range
$60-$156
Price range past year
Annual Return
-37.7%
Cumulative gain past year
| Period | TMDX Return | S&P 500 |
|---|---|---|
| 1m | -13.5% | +1.0% |
| 3m | +5.0% | +2.9% |
| 6m | -34.0% | +8.6% |
| 1y | -37.7% | +14.6% |
| ytd | -39.1% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMDX Fundamental Analysis
The revenue trajectory remains one of the strongest in medtech even as the stock has collapsed. Most recent quarterly revenue was $160.76 million in Q4 2025, up 32.18% year-over-year from $121.62 million, and the multi-quarter arc shows steady expansion: $143.54 million in Q1 2025, $157.37 million in Q2, $143.82 million in Q3, and $160.76 million in Q4. Sequentially the business is lumpy — Q3 dipped below Q2 — but the year-over-year growth rate of 32.18% and the fact that every 2025 quarter exceeded its 2024 counterpart ($96.85M, $114.31M, $108.76M, $121.62M) confirms a genuine growth engine, not a one-off. The product segment contributed $100.39 million of revenue, indicating that hardware/perfusion-set sales remain the core driver while the service/logistics layer builds underneath; the investment case hinges on whether that 30%+ growth can persist as the company scales into a larger, more capital-intensive organization.
Profitability is real but showing signs of strain at the margin. Q4 2025 net income was $105.38 million, though that figure was inflated by a -$83.75 million income tax benefit (a deferred-tax release) that pushed the effective tax rate deeply negative; normalized operating income was a more modest $21.27 million on a 13.23% operating margin. Gross margin has compressed from 61.47% in Q1 2025 to 58.11% in Q4 2025, and EBITDA margin fell from 29.48% in Q2 to 20.19% in Q4 — a clear downward trend that explains much of the recent investor anxiety and the post-earnings sell-off. The trailing net margin of 31.43% and gross margin of 59.92% look healthy in absolute terms and are respectable for a device company, but the direction of travel (gross margin down ~340bps over the year, operating margin down from 23.24% in Q2 to 13.23% in Q4) suggests scaling costs — R&D at $20.70 million and SG&A at $51.44 million in Q4 — are outrunning revenue leverage.
The balance sheet is a genuine strength that buys the company time. Cash at end of Q4 2025 stood at $488.87 million against total debt implied by a debt-to-equity ratio of 0.99, and the current ratio of 7.14 signals abundant short-term liquidity — the company can fund its growth internally for the foreseeable future. Free cash flow is positive but volatile: $133.59 million TTM, yet quarterly FCF swung from -$29.89 million in Q1 2025 to $82.53 million in Q2, $61.95 million in Q3, and just $19.00 million in Q4, with capital expenditure of $15.51 million in the latest quarter reflecting heavy investment in the logistics fleet. ROE of 40.22% is exceptional on paper but flattered by the tax benefit and a relatively thin equity base (equity multiplier of 2.26), while ROA of just 4.33% shows the asset base — planes, perfusion equipment, inventory — is capital-hungry. The FCF yield of roughly 3.2% on a $4.14 billion market cap is thin for a growth name, and the cash-flow-to-debt ratio of 0.073 highlights that debt service coverage, while manageable given the cash pile, is not a source of comfort.
Quarterly Revenue
$160764000.0B
2025-12
Revenue YoY Growth
+32.2%
YoY Comparison
Gross Margin
58.1%
Latest Quarter
Free Cash Flow
$133589000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMDX Overvalued?
Because net income is positive ($105.38 million in Q4 2025, EPS of $0.046 on a trailing basis), the PE ratio is the appropriate primary metric, and here the picture is unusual: the trailing PE of 21.72x is low for a 30%+ grower, but that trailing figure is distorted by the one-time tax benefit, while the forward PE of 31.40x reflects the market's expectation that normalized earnings will be lower than the optically depressed trailing multiple suggests. The gap between trailing (21.7x) and forward (31.4x) is inverted — forward earnings are expected to be lower than trailing — which tells you the market is not pricing accelerating earnings power but rather normalizing the tax-flattered base. On a cleaner basis, the PS ratio of 6.83x and EV/Sales of 4.56x are the more honest growth-adjusted yardsticks, and the PEG ratio of 0.051 is extraordinarily low, implying the market is paying very little per unit of expected growth — a signal that either the growth estimates are too optimistic or the stock is genuinely cheap.
Against the Medical-Devices industry, TMDX screens as a mixed bag rather than a clear premium or discount name. Its PS of 6.83x and EV/Sales of 4.56x are elevated relative to mature device peers that typically trade at 3-5x sales, but its gross margin of 59.92% and operating margin of 17.93% are competitive, and its 32.18% revenue growth is well above the mid-single-digit to low-double-digit growth of large-cap device companies — so a premium is defensible on growth grounds. The EV/EBITDA of 27.72x is rich versus a sector median in the high-teens, and the P/B of 8.74x is high, reflecting the asset-light-ish but capital-intensive logistics build-out. The key question is whether a ~4.6x EV/Sales multiple adequately compensates for margin compression; if gross margins keep sliding toward the mid-50s, the premium compresses, but if the kidney and European expansions re-accelerate growth, the multiple looks reasonable.
Historically, TMDX has traded at far richer multiples than today, which frames the current valuation as near the bottom of its own band. The PS ratio has collapsed from 25.89x at Q4 2025 to 6.83x now, and the PE has fallen from 9.88x (tax-distorted) at year-end to 21.72x on a normalized basis — but the more telling comparison is the multi-year PS arc: 62.97x in Q4 2022, 48.27x in Q3 2024, 26.61x in Q3 2025, and 6.83x today. That is a roughly 89% compression in the sales multiple over three years, meaning the market has aggressively de-rated the stock even as revenue grew. This is the classic setup where either the market is correctly pricing in a permanent growth-to-value transition and margin deterioration, or it has overshot and the stock is near a cyclical valuation trough — the 0.051 PEG and 6.83x PS suggest the latter is at least worth considering, but the falling gross margin argues caution.
PE
21.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~160x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin erosion and cash flow volatility. Gross margin has declined from 61.47% in Q1 2025 to 58.11% in Q4, and operating margin fell from 23.24% in Q2 to 13.23% in Q4, reflecting rising R&D ($20.70M) and SG&A ($51.44M) that are outpacing revenue growth. Free cash flow swung from -$29.89M in Q1 to $82.53M in Q2, $61.95M in Q3, and just $19.00M in Q4, with capex of $15.51M in Q4 for fleet investment. While cash of $488.87M and a current ratio of 7.14 provide a cushion, the debt-to-equity of 0.99 and cash-flow-to-debt of 0.073 mean debt service coverage is not a source of strength. Revenue concentration in the OCS product line ($100.39M of $160.76M) and dependence on continued 30%+ growth to justify the valuation add to the risk profile.
Market and competitive risks include valuation compression and high volatility. TMDX trades at an EV/EBITDA of 27.72x, rich versus the high-teens sector median, and a P/B of 8.74x, leaving little room for disappointment. The beta of 1.926 means the stock is nearly twice as volatile as the market, and its -54.34% relative strength vs. SPY over one year highlights severe underperformance. Competitive threats could emerge from alternative perfusion technologies or cold-storage improvements, while regulatory and reimbursement risks for new indications (kidney, Europe) remain. Recent news of an earnings miss and margin compression has already triggered a sharp sell-off, and the wide analyst target range ($65-$125) underscores uncertainty.
Worst-case scenario: a continued decline in gross margins toward the mid-50s, coupled with slower revenue growth as kidney and European expansions disappoint, could lead to further multiple compression. The 52-week low of $60.105 represents a potential downside of -15.1% from the current $70.78, and the analyst low target of $65 implies -8.2%. A break below the 52-week low could trigger momentum-driven selling toward the $50s, especially given the high beta and short ratio of 11.71 (indicating heavy short interest). In a severe scenario, the stock could retest its max drawdown level, implying a loss of 30-40% from current levels.
FAQ
The most severe risk is continued margin compression: gross margin fell from 61.47% to 58.11% in 2025, and operating margin halved from 23.24% to 13.23% in the same period. Second, the stock is in a severe downtrend with high volatility (beta 1.926) and is trading near its 52-week low of $60.105, which if broken could trigger further selling. Third, there is execution risk around the kidney and European expansions, which are critical to re-accelerating growth. Fourth, competitive threats from alternative perfusion technologies or improvements in cold storage could erode TMDX's moat. Finally, the high short interest (short ratio 11.71) indicates bearish sentiment that could amplify downside moves.
Our 12-month forecast has three scenarios: a base case (50% probability) with a target range of $85-$100, assuming revenue growth moderates to 25-30% and gross margins stabilize in the high-50s; a bull case (30% probability) targeting $98-$125, driven by successful kidney/European expansion and margin recovery; and a bear case (20% probability) targeting $60-$70, if margins fall below 55% and growth decelerates. The most likely scenario is the base case, which aligns with the analyst average target of $98.73. The key assumption is that gross margins stabilize above 58%, which would validate the growth story and support a modest re-rating from current oversold levels.
TMDX appears undervalued on a growth-adjusted basis but fairly valued to slightly expensive on earnings multiples. The PS ratio of 6.83x is well below its historical average of 62.97x in Q4 2022, and the PEG of 0.051 is extraordinarily low, suggesting the market is pricing minimal growth. However, the EV/EBITDA of 27.72x is rich versus the high-teens sector median, and the forward PE of 31.4x is above the trailing PE of 21.7x due to a one-time tax benefit inflating trailing earnings. The market seems to expect margin deterioration to continue, which is why the stock has de-rated. If margins stabilize, the valuation could re-rate higher; if they don't, the current multiple may not be as cheap as it looks.
TMDX is a high-risk, high-reward proposition that may be a good buy for long-term growth investors who can tolerate volatility. The stock trades at $70.78, down 38.8% over the past year, but the analyst consensus target of $98.73 implies 39.5% upside. The biggest downside risk is continued margin compression, which could push the stock toward the 52-week low of $60.105 (a 15% decline). However, the company's 32% revenue growth, $488.87M cash pile, and deeply compressed valuation (PS 6.83x vs. historical 62.97x) provide a margin of safety. It is best suited for investors with a 3-5 year horizon who believe in the OCS platform's long-term potential and can withstand a beta of 1.926.
TMDX is more suitable for long-term investment (minimum 3-5 years) given its early-stage growth profile, high volatility (beta 1.926), and no dividend. The company is still in the early innings of penetrating a large transplant market, with kidney and European expansions representing multi-year growth drivers. Short-term trading is risky due to the stock's sharp swings (max drawdown -58.76%) and current downtrend. However, for investors with a long horizon, the current valuation (PS 6.83x, PEG 0.051) and fortress balance sheet ($488.87M cash) offer an attractive entry point if they believe in the platform's long-term potential. A suggested minimum holding period is 3 years to allow for margin stabilization and new market contributions to materialize.